At the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the MPN Hub held a symposium, titled Advanced systemic mastocytosis: Redefining the disease, rethinking patient outcomes.
The symposium closed with a panel Q&A session with live audience participation. The panelists, Deepti H Radia, Andreas Reiter, Johannes Lübke, and Alessandro Vannucchi, discussed key challenges in advanced systemic mastocytosis (AdvSM), including underdiagnosis and complexities in the management of SM with an associated hematologic neoplasm (AHN), and mast cell leukemia (MCL). They also discussed emerging combination therapies and highlighted allogeneic hematopoietic stem cell transplantation (allo-HSCT) as the only potentially curative option in AdvSM, emphasizing the importance of optimal disease control prior to transplantation.
","author_name":"Scientific Education Support"}